Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Results from the Phase III ATTAIN-1 trial (NCT05869903) showed that the highest dose of orforglipron achieved an average ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

A new study in mice has found that muscle loss associated with weight loss from GLP-1 medications like Ozempic may not be as ...

Ozempic is linked to a potentially higher risk of vision loss in some studies. Doctors explain how GLP-1 drugs for diabetes ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

An oral GLP-1 induced up to 12.4% weight loss at 72 weeks for adults with overweight or obesity, according to topline results ...

GLP-1 receptor agonists are associated with risk reductions for dozens of diseases and conditions in addition to rapid weight ...